$ACT I can provide an analysis of **ACT (Actinium Pharmaceuticals)** based on recent trends, but keep in mind I don't have access to real-time data, so this will be a general outlook based on available patterns up to my knowledge cutoff.

**Bullish or Bearish:**

- **Bullish**: ACT has shown some positive movement in the past, especially with its clinical trials and partnerships. With the continued focus on its targeted therapies, there’s optimism about its potential upside in the biotech space. If positive news regarding its clinical studies or partnerships emerges, this could drive the stock higher.

- **Bearish**: On the flip side, biotechnology stocks are highly volatile, and ACT is no exception. Any negative trial results or financial struggles could significantly weigh down its value.

**Article Summary (under 150 words):**

Actinium Pharmaceuticals has made strides in its quest for targeted cancer treatments, particularly with its lead candidate, Iomab-B. The company’s focus on advanced therapies has positioned it well within the oncology field. Despite being in a competitive space, ACT’s recent partnerships and promising Phase 3 trials offer considerable upside potential. However, like many biotech firms, ACT remains a high-risk, high-reward stock due to clinical trial outcomes and market volatility.

**Target Price & Buy Price**:

- **Target Price**: $1.20 (with potential upside if clinical trials are successful)

- **Buy Price**: Under $0.75, for favorable risk/reward entry

**Correct Price ($0.7105)**:

At this price, ACT is at an intriguing entry point, but caution is warranted given the volatility in biotech stocks. If the stock dips below $0.70, it may provide a stronger buying opportunity for long-term investors willing to take on more risk.